Loading clinical trials...

COMPLETEDPHASE2

Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse

NCT00147160•Gustave Roussy, Cancer Campus, Grand Paris

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents

Eligibility

Age

4 - 21 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age from 4th birthday and younger than 21st birthday
•Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours
•Measurable and evaluable disease by the imaging criteria (MRI)
•Patient not previously treated by either of the two drugs

Exclusion Criteria

•Malignant brain stem tumours are excluded

Locations (2)

Institut Gustave-Roussy

Villejuif, France

Bristol Royal Hospital for Children

Bristol, United Kingdom

Key Dates

Start Date

October 1, 2003

Primary Completion Date

July 1, 2006

Completion Date

December 1, 2007

Last Updated

April 11, 2012

Enrollment

ESTIMATED participants

Conditions

Glioma

Interventions

Temozolomide, Cisplatinum

DRUG

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

NCT05099003

Malignant Glioma

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

Inclusion Criteria

Exclusion Criteria

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors